title: Cancer vaccines for the treatment and prevention of non small-cell lung cancer.
abstract: Cancer vaccines targeting non small-cell lung cancer (NSCLC) have been studied for decades; clinical trials, for the most part, have focused on the use of autologous and allogeneic whole-tumor cell vaccines. Recent advances in molecular biology and immunology, however, have allowed the identification of many tumor antigens involved in the generation of immunity to NSCLC. Although small-cell lung cancer (SCLC) is commonly thought of as an immunogenic tumor, it is now clear that NSCLC is also capable of eliciting an endogenous immune response in patients with the disease and, in fact, has a natural history that may make NSCLC more amenable to vaccine therapy as an adjuvant treatment strategy. This review will high-light the major components of the immune system that may potentially interact with tumor-associated proteins as well as outline the immunologic similarities and differences between SCLC and NSCLC. Tumor antigens that elicit immune responses in patients with NSCLC will be discussed. Finally, clinical trials of whole-tumor cell vaccines, both autologous and allogeneic, and tumor antigen-specific vaccines will also be discussed.
authors.affiliation: Division of Oncology, University of Washington, Seattle 98195-6527, USA. ndisis@u.washington.edu
authors.forename: M L
authors.initials: ML
authors.lastname: Disis
authors.forename: H L
authors.initials: HL
authors.lastname: West
authors.forename: K
authors.initials: K
authors.lastname: Schiffman